Clinical Trial Update: A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy results for ligelizumab in chronic spontaneous urticaria in Japanese patients inadequately controlled with H1 antihistamines; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Ligelizumab (ligelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2024-03-08